CSS LLC’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

CSS LLC’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$46.3K	–	1028
2023 Q1	$46.3K	Buy	+25,000	New	+$31K	﹤0.01%	611
2020 Q4	–	Sell	-29,000	Closed	-$237K	–	978
2020 Q3	$237K	Buy	+29,000	New	+$180K	0.01%	545

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CSS LLC's JNCE Position: Q2 2023 in Review

CSS LLC sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 25,000 shares — an estimated $46.3K sold.

CSS LLC first reported a position in JNCE in Q3 2020 and held it in 2 quarters. The position peaked at $237K in Q3 2020. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

CSS LLC reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
CSS LLC sold 25,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $46.3K.
CSS LLC first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
CSS LLC's Jounce Therapeutics, Inc. Common Stock position peaked at $237K in Q3 2020.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on CSS LLC's 13F filing for Q2 2023, filed 14 Aug 2023.